USPTO Examiner HIBBERT CATHERINE S - Art Unit 1658

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19200045METHOD TO PREVENT AND TREAT DIABETIC RETINOPATHY BY CALCIUM CHANNEL BLOCKERS, ANGIOTENSIN CONVERTING ENZYME INHIBITORS, AND ANGIOTENSIN RECEPTOR BLOCKERSMay 2025March 2026Abandon1010NoNo
19044943INSECT NEUROPEPTIDES 8February 2025October 2025Allow811NoNo
18444111MODIFIED U6 PROMOTER SYSTEM FOR TISSUE SPECIFIC EXPRESSIONFebruary 2024September 2025Abandon1901NoNo
18441502METHODS AND COMPOSITIONS FOR DETERMINING PLOIDYFebruary 2024February 2026Allow2411YesNo
18412406NEW METHODS AND SYSTEMS FOR TARGETED GENE MANIPULATIONJanuary 2024January 2026Allow2411NoNo
18521884GENERATION OF NEURAL STEM CELLS FROM HUMAN TROPHOBLAST STEM CELLSNovember 2023November 2025Abandon2421NoNo
18505163METHODS OF TREATING AMYOTROPHIC LATERAL SCLEROSIS (ALS)November 2023September 2025Allow2210NoNo
18502536COMPOSITIONS AND METHODS FOR MODULATING GAMMA-C-CYTOKINE ACTIVITYNovember 2023April 2025Abandon1701NoNo
18494883FACTOR H VARIANTS FOR TREATMENT OF DISEASEOctober 2023October 2024Allow1221YesNo
18492050INSECT NEUROPEPTIDES 8October 2023October 2024Allow1212YesNo
18467952Cas9/RNA Complexes for Inducing Modifications of Target Endogenous Nucleic Acid Sequences in Nucleuses of Eukaryotic CellsSeptember 2023September 2025Allow2421YesNo
18242406Hard Tissue TherapeuticsSeptember 2023January 2026Allow2811YesNo
18115847METHODS FOR PREVENTION AND TREATMENT OF ACUTE RENAL INJURYAugust 2023October 2025Abandon3111NoNo
18454780METHODS AND COMPOSITIONS FOR EGG WHITE PROTEIN PRODUCTIONAugust 2023March 2025Abandon1921YesNo
18233216Method for Predicting and Treating Clinically Significant Prostate CancerAugust 2023July 2025Abandon2420NoNo
18347342COMPOSITION FOR CONTROLLED RELEASE OF THERAPEUTIC AGENTSJuly 2023March 2025Allow2010NoNo
18345183METHOD OF INCREASING THE FUNCTION OF AN AAV VECTORJune 2023July 2024Abandon1310YesNo
18345191Method of Increasing the Function of an AAV VectorJune 2023August 2024Abandon1410NoNo
18337160TRANSPOSASE-MEDIATED IMAGING OF THE ACCESSIBLE GENOMEJune 2023February 2026Allow3220YesNo
18324843TRANSGENIC BACTERIA WITH EXPANDED AMINO ACID USAGE AND NUCLEIC ACID MOLECULES FOR USE IN THE SAMEMay 2023February 2025Allow2110NoNo
18200595METHODS OF TREATING AN ISCHEMIC DISEASEMay 2023August 2025Abandon2720NoNo
18315332EARLY POST-TRANSFECTION ISOLATION OF CELLS (EPIC) FOR BIOLOGICS PRODUCTIONMay 2023March 2026Abandon3430NoNo
18314050COMPOSITION FOR CLEAVING A TARGET DNA COMPRISING A GUIDE RNA SPECIFIC FOR THE TARGET DNA AND CAS PROTEIN-ENCODING NUCLEIC ACID OR CAS PROTEIN, AND USE THEREOFMay 2023March 2024Allow1050YesYes
18313482Engineered Guide RNA Sequences for In Situ Detection and SequencingMay 2023December 2024Abandon1901NoNo
18143547MDCK SUSPENSION CELL LINES IN SERUM-FREE, CHEMICALLY-DEFINED MEDIA FOR VACCINE PRODUCTIONMay 2023March 2026Allow3540YesNo
18139661AAV-MEDIATED EXPRESSION USING A SYNTHETIC PROMOTER AND ENHANCERApril 2023May 2025Abandon2411NoNo
18296446Orthogonal Cas9 Proteins for RNA-Guided Gene Regulation and EditingApril 2023November 2025Allow3121YesNo
18169473TREATMENT FOR DISEASES CAUSED BY RNA VIRUS SARS-COV-2February 2023November 2024Allow2120YesNo
18169368COLLAGEN 7 COMPOSITIONS AND METHODS OF USING THE SAMEFebruary 2023November 2025Abandon3311NoNo
18165138METHOD OF INCREASING THE FUNCTION OF AN AAV VECTORFebruary 2023December 2023Abandon1110NoNo
18040684TWO COMPONENT CO-ASSEMBLING TWO DIMENSIONAL PROTEIN STRUCTURESFebruary 2023March 2026Abandon3701NoNo
18156215EXPRESSION OF FC-CONTAINING PROTEINSJanuary 2023June 2025Allow2921NoNo
18014530HEPARANASE-NEUTRALIZING A54 MONOCLONAL ANTIBODYJanuary 2023December 2025Allow3610YesNo
18069651PH20 POLYPEPTIDE VARIANTS, FORMULATIONS AND USES THEREOFDecember 2022December 2025Abandon3621NoNo
18080093Methods and Compositions for Rapid Generation of Single and Multiplexed Reporters in CellsDecember 2022September 2024Allow2110YesNo
18061000METHOD OF INCREASING THE FUNCTION OF AN AAV VECTORDecember 2022July 2024Abandon2010NoNo
18057398Incretin Analogs and Uses ThereofNovember 2022March 2025Allow2811NoNo
18056823PEPTIDE-POLYNUCLEOTIDE-HYALURONIC ACID NANOPARTICLES AND METHODS FOR POLYNUCLEOTIDE TRANSFECTIONNovember 2022March 2026Allow4031YesNo
18056708METHOD FOR SOLUBLE EXPRESSION AND PURIFICATION OF HYDROPHOBINNovember 2022May 2025Allow3020NoNo
18054786METHOD OF INCREASING THE FUNCTION OF AN AAV VECTORNovember 2022January 2025Abandon2610NoNo
17998092CHIMERIC ANTIGEN RECEPTOR, MACROPHAGE EXPRESSING SAME, METHOD FOR ADJUSTING MACROPHAGE POLARIZATION, AND USE THEREOFNovember 2022October 2025Allow3610YesNo
18049593MODIFICATION OF RNA, PRODUCING AN INCREASED TRANSCRIPT STABILITY AND TRANSLATION EFFICIENCYOctober 2022May 2025Allow3032YesNo
18047953METHODS AND COMPOSITIONS FOR EGG WHITE PROTEIN PRODUCTIONOctober 2022February 2025Abandon2811NoNo
17919020Treatment for Diseases Caused by RNA VirusesOctober 2022October 2025Abandon3611NoNo
17918096PEPTIDES AND USES THEREOFOctober 2022December 2025Abandon3810YesNo
17915429METHOD OF TREATING CORONAVIRUS INFECTIONSSeptember 2022December 2025Abandon3810NoNo
179363773'-UTR SEQUENCES FOR STABILIZATION OF RNASeptember 2022July 2025Allow3311YesNo
17934661PROCESSES AND AGENTS FOR GLAUCOMASeptember 2022November 2025Abandon3801NoNo
17821713METHODS FOR TREATING PULMONARY DISEASE USING INTER-ALPHA INHIBITOR PROTEINSAugust 2022February 2025Allow3010YesNo
17879291METHOD FOR PRODUCING HYDROLYSED KERATINACEOUS MATERIALAugust 2022August 2025Allow3720NoNo
17811626DIRECTED EDITING OF CELLULAR RNA VIA NUCLEAR DELIVERY OF CRISPR/CAS9July 2022July 2024Allow2410NoNo
17855932Therapeutic APAC Molecule comprising Heparin Conjugated to a Plasma ProteinJuly 2022September 2024Allow2721YesNo
17845169METHODS AND COMPOSITIONS FOR DETERMINING PLOIDYJune 2022January 2024Allow1910YesNo
17749731Compositions Comprising Antimicrobial PeptidesMay 2022February 2024Allow2131YesNo
17748495Materials and Methods for Treatment of Duchenne Muscular DystrophyMay 2022February 2024Allow2110YesNo
17777159A SYNERGISTIC FORMULATION FOR MANAGEMENT OF RESPIRATORY PATHOGENS INCLUDING CORONAVIRUSESMay 2022March 2026Abandon4611NoNo
17743526Polypeptide Containing DNA-Binding DomainMay 2022March 2025Allow3421YesNo
17729751MODIFIED U6 PROMOTER SYSTEM FOR TISSUE SPECIFIC EXPRESSIONApril 2022November 2023Allow1900YesNo
17692807Methods of Treating Disease by Skewing Macrophage Phenotype with Alternating Electric FieldsMarch 2022July 2025Allow4031YesNo
17692925AAV DELIVERY OF NUCLEOBASE EDITORSMarch 2022February 2026Allow4831YesNo
17753423POLYPEPTIDE MONOLAYER WITH HIGH POTENTIAL AND SUPER-HYDROPHILICITY, AND PREPARATION METHOD AND APPLICATION THEREOFMarch 2022January 2026Abandon4721NoNo
17677827METHODS OF TREATING OR PREVENTING PYRUVATE KINASE DEFICIENCYFebruary 2022July 2024Allow2920YesNo
17672744RNA-Guided Human Genome EngineeringFebruary 2022September 2022Allow710YesNo
17634178THERAPEUTIC PEPTIDESFebruary 2022October 2025Abandon4401NoNo
17590737INDUCIBLE EXPRESSION FROM TRANSPOSON-BASED VECTORS AND USESFebruary 2022April 2023Allow1400YesNo
17589547Compositions for Treatment of Vascular DiseaseJanuary 2022June 2024Allow2820NoNo
17630994DNA-AFFIBODY-DRUG NANOPARTICLES FOR INHIBITING THE METASTASIS OF CANCER CELLS OVEREXPRESSING HER2January 2022April 2025Allow3911YesNo
17575488RECOMBINANT ADENOVIRUSES CARRYING TRANSGENESJanuary 2022December 2024Allow3521YesNo
17571550METHOD FOR TREATING COLORECTAL CANCERJanuary 2022April 2025Abandon3910NoNo
17568183TYPE VI-E AND TYPE VI-F CRISPR-CAS SYSTEM AND USES THEREOFJanuary 2022July 2025Allow4231NoNo
17568698INSULIN ANALOGSJanuary 2022May 2025Allow4011NoNo
17624523INHIBITORS OF IL-15 AND THEIR USE IN TREATING AUTOIMMUNE/INFLAMMATORY DISORDERSJanuary 2022July 2025Allow4311YesNo
17623748STABLE FORMULATIONS OF RECOMBINANT PROTEINSDecember 2021November 2025Allow4631YesNo
17563633COMPOSITION FOR TREATMENT OF CRIGLER-NAJJAR SYNDROMEDecember 2021February 2024Allow2611NoNo
17554182CONCATEMERIC PEPTIDE EPITOPE RNASDecember 2021March 2024Allow2710YesNo
17541454Methods of Host Cell ModificationDecember 2021May 2025Allow4131NoNo
17541737Therapeutic Compositions Directed To Host Mirna For The Treatment Of Sars-Cov-2 (Covid-19) InfectionDecember 2021January 2024Abandon2610NoNo
17614085Raw Material Liquid Concentration SystemNovember 2021June 2025Allow4210NoNo
17532385GENERATION OF NEURAL STEM CELLS FROM HUMAN TROPHOBLAST STEM CELLSNovember 2021September 2023Allow2210YesNo
17525344Compositions Comprising Antimicrobial PeptidesNovember 2021February 2024Allow2741YesNo
17495233DEVELOPMENT OF OPTIMIZED RECOMBINANT EXPRESSION CONSTRUCTOctober 2021July 2024Allow3331YesNo
17492229ADENO-ASSOCIATED VIRUS (AAV) SEROTYPE 8 SEQUENCES, VECTORS CONTAINING SAME, AND USES THEREFOROctober 2021May 2022Allow811YesNo
17599618COMBINATION THERAPY TO TREAT CANCER AND USES THEREOFSeptember 2021February 2025Abandon4010NoNo
17478824Fc Receptor-ACE2 Conjugates and Use ThereofSeptember 2021September 2024Abandon3621NoNo
17447974CELL LINES EXPRESSING INSERTED SECRETABLE REPORTER GENES AT MULTIPLE STAGES OF DIFFERENTIATIONSeptember 2021August 2024Abandon3520NoNo
17477918Hard Tissue TherapeuticsSeptember 2021August 2023Allow2311YesNo
17437216METHODS OF IMPROVING FISH FEED CONVERSION RATE AND SURVIVALSeptember 2021February 2025Abandon4101NoNo
17404286GENE EDITING THROUGH MICROFLUIDIC DELIVERYAugust 2021February 2024Allow3010YesNo
17427370COMPOSITIONS AND METHODS FOR TREATING OR LIMITING DEVELOPMENT OF AGE-RELATED MACULAR DEGENERATIONJuly 2021January 2024Allow3011YesNo
17382855SKIN SOOTHING COMPOSITION INCLUDING EXOSOMES DERIVED FROM NATURAL EXTRACTJuly 2021June 2025Abandon4761YesNo
17417587ENGINEERED LYSIN-HUMAN DEFENSIN PROTEINJune 2021January 2026Allow5530YesNo
17319289DETECTION OF NUCLEIC ACIDSMay 2021September 2025Abandon5241NoNo
17245437METHODS FOR SCARLESS INTRODUCTION OF TARGETED MODIFICATIONS INTO TARGETING VECTORSApril 2021July 2022Allow1521YesNo
17236660ARTIFICIALLY-MANIPULATED NEOVASCULARIZATION REGULATORY SYSTEMApril 2021March 2024Allow3411NoNo
17284299APOM-FC FUSION PROTEINS FOR TREATING LUNG DISEASESApril 2021May 2025Allow4930YesNo
17281796COMPOSITIONS AND METHODS FOR PREVENTION AND REDUCTION OF METASTASISMarch 2021August 2025Abandon5321NoNo
17204412THERAPEUTIC COMBINATION COMPRISING A PULMONARY SURFACTANT AND A STEROID FOR THE PROPHYLAXIS OF BPDMarch 2021December 2025Allow5760YesNo
17204782THERMAL BIOSWITCHES AND RELATED GENETIC CIRCUITS, VECTORS, CELLS, COMPOSITIONS, METHODS AND SYSTEMSMarch 2021September 2023Allow3010YesNo
17196504COMPOSITIONS FOR TREATMENT OF VASCULAR DISEASEMarch 2021December 2021Allow911YesNo
17190954EXPRESSION FROM TRANSPOSON-BASED VECTORS AND USESMarch 2021March 2023Allow2500YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner HIBBERT, CATHERINE S.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
4
Examiner Affirmed
1
(25.0%)
Examiner Reversed
3
(75.0%)
Reversal Percentile
88.9%
Higher than average

What This Means

With a 75.0% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.

Strategic Value of Filing an Appeal

Total Appeal Filings
27
Allowed After Appeal Filing
5
(18.5%)
Not Allowed After Appeal Filing
22
(81.5%)
Filing Benefit Percentile
22.8%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 18.5% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner HIBBERT, CATHERINE S - Prosecution Strategy Guide

Executive Summary

Examiner HIBBERT, CATHERINE S works in Art Unit 1658 and has examined 216 patent applications in our dataset. With an allowance rate of 82.9%, this examiner has an above-average tendency to allow applications. Applications typically reach final disposition in approximately 46 months.

Allowance Patterns

Examiner HIBBERT, CATHERINE S's allowance rate of 82.9% places them in the 56% percentile among all USPTO examiners. This examiner has an above-average tendency to allow applications.

Office Action Patterns

On average, applications examined by HIBBERT, CATHERINE S receive 2.69 office actions before reaching final disposition. This places the examiner in the 79% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by HIBBERT, CATHERINE S is 46 months. This places the examiner in the 10% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +41.4% benefit to allowance rate for applications examined by HIBBERT, CATHERINE S. This interview benefit is in the 88% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 26.9% of applications are subsequently allowed. This success rate is in the 46% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 30.2% of cases where such amendments are filed. This entry rate is in the 44% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 133.3% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 85% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 83.3% of appeals filed. This is in the 76% percentile among all examiners. Of these withdrawals, 70.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 74.7% are granted (fully or in part). This grant rate is in the 80% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 3.2% of allowed cases (in the 80% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 10.1% of allowed cases (in the 89% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Request pre-appeal conferences: PACs are highly effective with this examiner. Before filing a full appeal brief, request a PAC to potentially resolve issues without full PTAB review.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.